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Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancer With High 
Tumor Mutation Burden
Abstract 
Introduction: The highly selective ALK inhibitor alectinib is standard therapy for ALK-
positive lung cancers; however, some tumors quickly develop resistance. Here, we 
investigated the mechanism associated with rapid acquisition of resistance using clinical 
samples.  Methods: Autopsied samples were obtained from lung, liver, and renal tumors 
from a 51-year-old male patient with advanced ALK-positive lung cancer and who had 
acquired resistance to alectinib in only 3 months. We established an alectinib-resistant 
cell line (ABC-14) from pleural effusion and an alectinib/crizotinib-resistant cell line 
(ABC-17) and patient-derived xenograft (PDX) model from liver tumors. Additionally, 
we performed next-generation sequencing (NGS), direct DNA sequencing, and 
quantitative real-time reverse-transcription polymerase chain reaction. 
Results: ABC-14 cells harbored no ALK mutations and were sensitive to crizotinib while also 
exhibiting MET gene amplification and amphiregulin overexpression. Additionally, 
combined treatment with crizotinib/erlotinib inhibited cell growth. ABC-17 and PDX 
tumors harbored ALK G1202R, and PDX tumors metastasized to multiple organs in vivo, 
whereas the third generation ALK-inhibitor, lorlatinib, diminished tumor growth in vitro 
and in vivo. NGS indicated high tumor mutation burden (TMB) and heterogeneous 
tumor evolution. The autopsied lung tumors harbored ALK G1202R (c. 3604 G>A) and 
the right renal metastasis harbored ALK G1202R (c. 3604 G>C); the mutation thus 
comprised different codon changes.  Conclusions: High TMB and heterogeneous tumor 
evolution might be responsible for rapid acquisition of alectinib resistance. Timely lorlatinib 
administration or combined therapy with an ALK inhibitor and other receptor tyrosine-
kinase inhibitors might constitute a potent strategy. 
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